Top

Current Breast Cancer Reports

Published in:

01-09-2020 | Breast Cancer | Breast Cancer Disparities (LA Newman, Section Editor)

Breast Cancer Health Disparities in Hispanics/Latinas

Authors: Silvia J. Serrano-Gomez, Maria Carolina Sanabria-Salas, Laura Fejerman

Published in: Current Breast Cancer Reports | Issue 3/2020

Abstract

Purpose of Review

Breast cancer incidence and mortality rates are lower in some Hispanic/Latino subpopulations compared with non-Hispanic White women. However, studies suggest that the risk of breast cancer–specific mortality is higher in USA Hispanics/Latinas. In this review we summarized current knowledge on factors associated with breast cancer incidence and risk of mortality in women of Hispanic/Latino origin.

Recent Findings

Associative studies have proposed a multiplicity of factors likely contributing to differences in breast cancer incidence and survival between population groups, including socioeconomic/sociodemographic factors and lifestyle choices as well as access to and quality of care. Reports of association between global genetic ancestry overall as well as subtype-specific breast cancer risk among Hispanic/Latinas suggest that incidence and subtype distribution could result from differential exposure to environmental and lifestyle-related factors correlated with genetic ancestry as well as germline genetic variation.

Summary

Hispanic/Latinos in the USA have been largely underrepresented in cancer research. It is important to implement inclusive programs that facilitate the access of this population to health services and that also include education programs for the community on the importance of screening. In addition, it is important to continue promoting the inclusion of Hispanics/Latinos in genomic studies that allow understanding the biological behavior of this disease in the context of all human genetic diversity.

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492This is the most recent report from Globocan on cancer statistics worldwide. CrossRefPubMed

DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A, et al. Breast cancer statistics, 2019. CA Cancer J Clin. 2019;69(6):438–51. https://doi.org/10.3322/caac.21583.CrossRefPubMed

Chlebowski RT, Chen Z, Anderson GL, Rohan T, Aragaki A, Lane D, et al. Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst. 2005;97(6):439–48. https://doi.org/10.1093/jnci/dji064.CrossRefPubMed

Fejerman L, Chen GK, Eng C, Huntsman S, Hu D, Williams A, et al. Admixture mapping identifies a locus on 6q25 associated with breast cancer risk in US Latinas. Hum Mol Genet. 2012;21(8):1907–17. https://doi.org/10.1093/hmg/ddr617.CrossRefPubMedPubMedCentral

• Fejerman L, Ahmadiyeh N, Hu D, Huntsman S, Beckman KB, Caswell JL, et al. Genome-wide association study of breast cancer in Latinas identifies novel protective variants on 6q25. Nat Commun. 2014;5:5260. https://doi.org/10.1038/ncomms6260This is the first GWAS of breast cancer in Latinos and reported an Indigenous American–specific protective variant located near theESR1gene. CrossRefPubMed

Hoffman J, Fejerman L, Hu D, Hunstman S, Li M, John E, et al. Identification of novel common breast cancer risk variants in Latinas at the 6q25 locus. bioRxiv. 2018.

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. https://doi.org/10.3322/caac.21551.CrossRefPubMed

Miller KD, Goding Sauer A, Ortiz AP, Fedewa SA, Pinheiro PS, Tortolero-Luna G, et al. Cancer statistics for Hispanics/Latinos, 2018. CA Cancer J Clin. 2018;68(6):425–45. https://doi.org/10.3322/caac.21494.CrossRefPubMed

DeSantis CE, Ma J, Goding Sauer A, Newman LA, Jemal A. Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin. 2017;67(6):439–48. https://doi.org/10.3322/caac.21412.CrossRefPubMed

10.

Yedjou CG, Tchounwou PB, Payton M, Miele L, Fonseca DD, Lowe L, et al. Assessing the racial and ethnic disparities in breast cancer mortality in the United States. Int J Environ Res Public Health. 2017;14(5):E486. https://doi.org/10.3390/ijerph14050486.CrossRefPubMed

11.

Ooi SL, Martinez ME, Li CI. Disparities in breast cancer characteristics and outcomes by race/ethnicity. Breast Cancer Res Treat. 2011;127(3):729–38. https://doi.org/10.1007/s10549-010-1191-6.CrossRefPubMed

12.

Iqbal J, Ginsburg O, Rochon PA, Sun P, Narod SA. Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States. JAMA. 2015;313(2):165–73. https://doi.org/10.1001/jama.2014.17322.CrossRefPubMed

13.

• Alvidrez J, Castille D, Laude-Sharp M, Rosario A, Tabor D. The National Institute on Minority Health and Health Disparities Research Framework. Am J Public Health. 2019;109(S1):S16–20. https://doi.org/10.2105/AJPH.2018.304883Multidimensional/multilevel framework proposed by NIMHD to think about health disparities. CrossRefPubMedPubMedCentral

14.

Conomos MP, Laurie CA, Stilp AM, Gogarten SM, McHugh CP, Nelson SC, et al. Genetic diversity and association studies in US Hispanic/Latino populations: applications in the Hispanic Community Health Study/Study of Latinos. Am J Hum Genet. 2016;98(1):165–84. https://doi.org/10.1016/j.ajhg.2015.12.001.CrossRefPubMedPubMedCentral

15.

G Soares-Souza, V Borda, F Kehdy & E Tarazona-Santos. Admixture, genetics and complex diseases in Latin Americans and US Hispanics. Current Genetic Medicine Reports. 2018.

16.

Bryc K, Velez C, Karafet T, Moreno-Estrada A, Reynolds A, Auton A, et al. Colloquium paper: genome-wide patterns of population structure and admixture among Hispanic/Latino populations. Proc Natl Acad Sci U S A. 2010;107(Suppl 2):8954–61. https://doi.org/10.1073/pnas.0914618107.CrossRefPubMedPubMedCentral

17.

Ruiz-Linares A, Adhikari K, Acuna-Alonzo V, Quinto-Sanchez M, Jaramillo C, Arias W, et al. Admixture in Latin America: geographic structure, phenotypic diversity and self-perception of ancestry based on 7,342 individuals. PLoS Genet. 2014;10(9):e1004572. https://doi.org/10.1371/journal.pgen.1004572.CrossRefPubMedPubMedCentral

18.

Avena S, Via M, Ziv E, Pérez-Stable EJ, Gignoux CR, Dejean C, et al. Heterogeneity in genetic admixture across different regions of Argentina. PLoS One. 2012;7(4):e34695. https://doi.org/10.1371/journal.pone.0034695.CrossRefPubMedPubMedCentral

19.

Moreno-Estrada A, Gignoux CR, Fernández-López JC, Zakharia F, Sikora M, Contreras AV, et al. Human genetics. The genetics of Mexico recapitulates Native American substructure and affects biomedical traits. Science. 2014;344(6189):1280–5. https://doi.org/10.1126/science.1251688.CrossRefPubMedPubMedCentral

20.

Homburger JR, Moreno-Estrada A, Gignoux CR, Nelson D, Sanchez E, Ortiz-Tello P, et al. Genomic insights into the ancestry and demographic history of South America. PLoS Genet. 2015;11(12):e1005602. https://doi.org/10.1371/journal.pgen.1005602.CrossRefPubMedPubMedCentral

21.

Society AAC. Cancer Facts & Figures for Hispanics/Latinos 2018–2020. 2018.

22.

Di Sibio A, Abriata G, Forman D, Sierra MS. Female breast cancer in Central and South America. Cancer Epidemiol. 2016;44(Suppl 1):S110–S20. https://doi.org/10.1016/j.canep.2016.08.010.CrossRefPubMed

23.

Fejerman L, John EM, Huntsman S, Beckman K, Choudhry S, Perez-Stable E, et al. Genetic ancestry and risk of breast cancer among U.S. Latinas. Cancer Res. 2008;68(23):9723–8. https://doi.org/10.1158/0008-5472.CAN-08-2039.CrossRefPubMedPubMedCentral

24.

Fejerman L, Romieu I, John EM, Lazcano-Ponce E, Huntsman S, Beckman KB, et al. European ancestry is positively associated with breast cancer risk in Mexican women. Cancer Epidemiol Biomark Prev. 2010;19(4):1074–82. https://doi.org/10.1158/1055-9965.EPI-09-1193.CrossRef

25.

Hoffman J, Fejerman L, Hu D, Huntsman S, Li M, John EM, et al. Identification of novel common breast cancer risk variants at the 6q25 locus among Latinas. Breast Cancer Res. 2019;21(1):3. https://doi.org/10.1186/s13058-018-1085-9.CrossRefPubMedPubMedCentral

26.

Slattery ML, John EM, Torres-Mejia G, Lundgreen A, Herrick JS, Baumgartner KB, et al. Genetic variation in genes involved in hormones, inflammation and energetic factors and breast cancer risk in an admixed population. Carcinogenesis. 2012;33(8):1512–21. https://doi.org/10.1093/carcin/bgs163.CrossRefPubMedPubMedCentral

27.

Fejerman L, Stern MC, Ziv E, John EM, Torres-Mejia G, Hines LM, et al. Genetic ancestry modifies the association between genetic risk variants and breast cancer risk among Hispanic and non-Hispanic white women. Carcinogenesis. 2013;34(8):1787–93. https://doi.org/10.1093/carcin/bgt110.CrossRefPubMedPubMedCentral

28.

Slattery ML, Hines LH, Lundgreen A, Baumgartner KB, Wolff RK, Stern MC, et al. Diet and lifestyle factors interact with MAPK genes to influence survival: the Breast Cancer Health Disparities Study. Cancer Causes Control. 2014;25(9):1211–25. https://doi.org/10.1007/s10552-014-0426-y.CrossRefPubMedPubMedCentral

29.

Slattery ML, John EM, Torres-Mejia G, Lundgreen A, Lewinger JP, Stern MC, et al. Angiogenesis genes, dietary oxidative balance and breast cancer risk and progression: the Breast Cancer Health Disparities Study. Int J Cancer. 2014;134(3):629–44. https://doi.org/10.1002/ijc.28377.CrossRefPubMed

30.

Slattery ML, John EM, Stern MC, Herrick J, Lundgreen A, Giuliano AR, et al. Associations with growth factor genes (FGF1, FGF2, PDGFB, FGFR2, NRG2, EGF, ERBB2) with breast cancer risk and survival: the Breast Cancer Health Disparities Study. Breast Cancer Res Treat. 2013;140(3):587–601. https://doi.org/10.1007/s10549-013-2644-5.CrossRefPubMedPubMedCentral

31.

Armstrong N, Ryder S, Forbes C, Ross J, Quek RG. A systematic review of the international prevalence of. Clin Epidemiol. 2019;11:543–61. https://doi.org/10.2147/CLEP.S206949.CrossRefPubMedPubMedCentral

32.

• Lynce F, Graves KD, Jandorf L, Ricker C, Castro E, Moreno L, et al. Genomic disparities in breast cancer among Latinas. Cancer Control. 2016;23(4):359–72 Comprehensive review on genomic disparities in breast cancer among Latinas. CrossRefPubMed

33.

Cruz-Correa M, Pérez-Mayoral J, Dutil J, Echenique M, Mosquera R, Rivera-Román K, et al. Hereditary cancer syndromes in Latino populations: genetic characterization and surveillance guidelines. Hered Cancer Clin Pract. 2017;15:3. https://doi.org/10.1186/s13053-017-0063-z.CrossRefPubMedPubMedCentral

34.

• Dutil J, Golubeva VA, Pacheco-Torres AL, Diaz-Zabala HJ, Matta JL, Monteiro AN. The spectrum of BRCA1 and BRCA2 alleles in Latin America and the Caribbean: a clinical perspective. Breast Cancer Res Treat. 2015;154(3):441–53. https://doi.org/10.1007/s10549-015-3629-3Comprehensive description of previous studies reporting on the spectrum of BRCA alleles in Latin America and the Caribbean. CrossRefPubMedPubMedCentral

35.

Zavala VA, Serrano-Gomez SJ, Dutil J, Fejerman L. Genetic epidemiology of breast cancer in Latin America. Genes (Basel). 2019;10(2):E153. https://doi.org/10.3390/genes10020153.CrossRef

36.

John EM, Miron A, Gong G, Phipps AI, Felberg A, Li FP, et al. Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups. JAMA. 2007;298(24):2869–76. https://doi.org/10.1001/jama.298.24.2869.CrossRefPubMed

37.

Weitzel JN, Clague J, Martir-Negron A, Ogaz R, Herzog J, Ricker C, et al. Prevalence and type of BRCA mutations in Hispanics undergoing genetic cancer risk assessment in the southwestern United States: a report from the Clinical Cancer Genetics Community Research Network. J Clin Oncol. 2013;31(2):210–6. https://doi.org/10.1200/JCO.2011.41.0027.CrossRefPubMed

38.

Oliver J, Quezada Urban R, Franco Cortés CA, Díaz Velásquez CE, Montealegre Paez AL, Pacheco-Orozco RA, et al. Latin American Study of Hereditary Breast and Ovarian Cancer. Front Oncol. 2019;9:1429. https://doi.org/10.3389/fonc.2019.01429.CrossRefPubMedPubMedCentral

39.

• Weitzel JN, Neuhausen SL, Adamson A, Tao S, Ricker C, Maoz A, et al. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer. Cancer. 2019;125(16):2829–36. https://doi.org/10.1002/cncr.32083Description of rare high penetrance mutations among BRCA-negative Hispanics with breast cancer. CrossRefPubMed

40.

Keegan TH, John EM, Fish KM, Alfaro-Velcamp T, Clarke CA, Gomez SL. Breast cancer incidence patterns among California Hispanic women: differences by nativity and residence in an enclave. Cancer Epidemiol Biomarkers Prevent : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2010;19(5):1208–18. https://doi.org/10.1158/1055-9965.EPI-10-0021.CrossRef

41.

John EM, Phipps AI, Davis A, Koo J. Migration history, acculturation, and breast cancer risk in Hispanic women. Cancer Epidemiol Biomark Prev. 2005;14(12):2905–13. https://doi.org/10.1158/1055-9965.EPI-05-0483.CrossRef

42.

• Pinheiro PS, Sherman RL, Trapido EJ, Fleming LE, Huang Y, Gomez-Marin O, et al. Cancer incidence in first generation U.S. Hispanics: Cubans, Mexicans, Puerto Ricans, and new Latinos. Cancer Epidemiol Biomark Prev. 2009;18(8):2162–9. https://doi.org/10.1158/1055-9965.EPI-09-0329Showed how cancer rates vary among Hispanic subpopulations by country of origin and immigration status. CrossRef

43.

Conroy SM, Shariff-Marco S, Koo J, Yang J, Keegan TH, Sangaramoorthy M, et al. Racial/ethnic differences in the impact of neighborhood social and built environment on breast cancer risk: the Neighborhoods and Breast Cancer Study. Cancer Epidemiol Biomark Prev. 2017;26(4):541–52. https://doi.org/10.1158/1055-9965.EPI-16-0935.CrossRef

44.

Dubowitz T, Subramanian SV, Acevedo-Garcia D, Osypuk TL, Peterson KE. Individual and neighborhood differences in diet among low-income foreign and U.S.-born women. Womens Health Issues. 2008;18(3):181–90. https://doi.org/10.1016/j.whi.2007.11.001.CrossRefPubMedPubMedCentral

45.

McCormack VA, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomark Prev. 2006;15(6):1159–69. https://doi.org/10.1158/1055-9965.EPI-06-0034.CrossRef

46.

Tehranifar P, Rodriguez CB, April-Sanders AK, Desperito E, Schmitt KM. Migration history, language acculturation, and mammographic breast density. Cancer Epidemiol Biomark Prev. 2018;27(5):566–74. https://doi.org/10.1158/1055-9965.EPI-17-0885.CrossRef

47.

Akinyemiju TF, Genkinger JM, Farhat M, Wilson A, Gary-Webb TL, Tehranifar P. Residential environment and breast cancer incidence and mortality: a systematic review and meta-analysis. BMC Cancer. 2015;15:191. https://doi.org/10.1186/s12885-015-1098-z.CrossRefPubMedPubMedCentral

48.

Yost K, Perkins C, Cohen R, Morris C, Wright W. Socioeconomic status and breast cancer incidence in California for different race/ethnic groups. Cancer Causes Control. 2001;12(8):703–11. https://doi.org/10.1023/a:1011240019516.CrossRefPubMed

49.

Osypuk TL, Diez Roux AV, Hadley C, Kandula NR. Are immigrant enclaves healthy places to live? The multi-ethnic study of atherosclerosis. Soc Sci Med. 2009;69(1):110–20. https://doi.org/10.1016/j.socscimed.2009.04.010.CrossRefPubMedPubMedCentral

50.

Pruitt SL, Tiro JA, Xuan L, Lee SJ. Hispanic and immigrant paradoxes in U.S. breast cancer mortality: impact of neighborhood poverty and Hispanic density. Int J Environ Res Public Health. 2016;13(12):E1238. https://doi.org/10.3390/ijerph13121238.CrossRefPubMed

51.

Pinheiro PS, Williams M, Miller EA, Easterday S, Moonie S, Trapido EJ. Cancer survival among Latinos and the Hispanic paradox. Cancer Causes Control. 2011;22(4):553–61. https://doi.org/10.1007/s10552-011-9727-6.CrossRefPubMed

52.

Li CI, Malone KE, Daling JR. Differences in breast cancer stage, treatment, and survival by race and ethnicity. Arch Intern Med. 2003;163(1):49–56. https://doi.org/10.1001/archinte.163.1.49.CrossRefPubMed

53.

Rodriguez-Alcalá ME, Qin H, Jeanetta S. The role of acculturation and social capital in access to health care: a meta-study on Hispanics in the US. J Community Health. 2019;44(6):1224–52. https://doi.org/10.1007/s10900-019-00692-z.CrossRefPubMed

54.

Press R, Carrasquillo O, Sciacca RR, Giardina EG. Racial/ethnic disparities in time to follow-up after an abnormal mammogram. J Women's Health (Larchmt). 2008;17(6):923–30. https://doi.org/10.1089/jwh.2007.0402.CrossRef

55.

Goldman LE, Walker R, Hubbard R, Kerlikowske K, Consortium BCS. Timeliness of abnormal screening and diagnostic mammography follow-up at facilities serving vulnerable women. Med Care. 2013;51(4):307–14. https://doi.org/10.1097/MLR.0b013e318280f04c.CrossRefPubMedPubMedCentral

56.

Banegas MP, Tao L, Altekruse S, Anderson WF, John EM, Clarke CA, et al. Heterogeneity of breast cancer subtypes and survival among Hispanic women with invasive breast cancer in California. Breast Cancer Res Treat. 2014;144(3):625–34. https://doi.org/10.1007/s10549-014-2882-1.CrossRefPubMedPubMedCentral

57.

Hines LM, Risendal B, Byers T, Mengshol S, Lowery J, Singh M. Ethnic disparities in breast tumor phenotypic subtypes in Hispanic and non-Hispanic white women. J Women's Health (Larchmt). 2011;20(10):1543–50. https://doi.org/10.1089/jwh.2010.2558.CrossRef

58.

Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LA, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014;106(5):dju055. https://doi.org/10.1093/jnci/dju055.CrossRefPubMedPubMedCentral

59.

Parise CA, Bauer KR, Caggiano V. Variation in breast cancer subtypes with age and race/ethnicity. Crit Rev Oncol Hematol. 2010;76(1):44–52. https://doi.org/10.1016/j.critrevonc.2009.09.002.CrossRefPubMed

60.

Serrano-Gomez SJ, Fejerman L, Zabaleta J. Breast cancer in Latinas: a focus on intrinsic subtypes distribution. Cancer Epidemiol Biomark Prev. 2018;27(1):3–10. https://doi.org/10.1158/1055-9965.EPI-17-0420.CrossRef

61.

Wells KJ, Roetzheim RG. Health disparities in receipt of screening mammography in Latinas: a critical review of recent literature. Cancer Control. 2007;14(4):369–79. https://doi.org/10.1177/107327480701400407.CrossRefPubMed

62.

Society AC. Breast Cancer Facts & Figures 2017–2018. 2017.

63.

Purc-Stephenson RJ, Gorey KM. Lower adherence to screening mammography guidelines among ethnic minority women in America: a meta-analytic review. Prev Med. 2008;46(6):479–88. https://doi.org/10.1016/j.ypmed.2008.01.001.CrossRefPubMedPubMedCentral

64.

Warner ET, Tamimi RM, Hughes ME, Ottesen RA, Wong YN, Edge SB, et al. Time to diagnosis and breast cancer stage by race/ethnicity. Breast Cancer Res Treat. 2012;136(3):813–21. https://doi.org/10.1007/s10549-012-2304-1.CrossRefPubMedPubMedCentral

65.

Molina Y, Plascak JJ, Patrick DL, Bishop S, Coronado GD, Beresford SA. Neighborhood predictors of mammography barriers among US-based Latinas. J Racial Ethn Health Disparities. 2017;4(2):233–42. https://doi.org/10.1007/s40615-016-0222-3.CrossRefPubMed

66.

Clarke TC, Endeshaw M, Duran D, Saraiya M. Breast cancer screening among women by nativity, birthplace, and length of time in the United States. Natl Health Stat Report. 2019;129:1–15.

67.

Shavers VL, Brown ML. Racial and ethnic disparities in the receipt of cancer treatment. J Natl Cancer Inst. 2002;94(5):334–57. https://doi.org/10.1093/jnci/94.5.334.CrossRefPubMed

68.

Chen L, Li CI. Racial disparities in breast cancer diagnosis and treatment by hormone receptor and HER2 status. Cancer Epidemiol Biomark Prev. 2015;24(11):1666–72. https://doi.org/10.1158/1055-9965.EPI-15-0293.CrossRef

69.

Wu XC, Lund MJ, Kimmick GG, Richardson LC, Sabatino SA, Chen VW, et al. Influence of race, insurance, socioeconomic status, and hospital type on receipt of guideline-concordant adjuvant systemic therapy for locoregional breast cancers. J Clin Oncol. 2012;30(2):142–50. https://doi.org/10.1200/JCO.2011.36.8399.CrossRefPubMed

70.

Friese CR, Pini TM, Li Y, Abrahamse PH, Graff JJ, Hamilton AS, et al. Adjuvant endocrine therapy initiation and persistence in a diverse sample of patients with breast cancer. Breast Cancer Res Treat. 2013;138(3):931–9. https://doi.org/10.1007/s10549-013-2499-9.CrossRefPubMedPubMedCentral

71.

Warner ET, Tamimi RM, Hughes ME, Ottesen RA, Wong YN, Edge SB, et al. Racial and ethnic differences in breast cancer survival: mediating effect of tumor characteristics and sociodemographic and treatment factors. J Clin Oncol. 2015;33(20):2254–61. https://doi.org/10.1200/JCO.2014.57.1349.CrossRefPubMedPubMedCentral

72.

Neugut AI, Subar M, Wilde ET, Stratton S, Brouse CH, Hillyer GC, et al. Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. J Clin Oncol. 2011;29(18):2534–42. https://doi.org/10.1200/JCO.2010.33.3179.CrossRefPubMedPubMedCentral

73.

Daly B, Olopade OI, Hou N, Yao K, Winchester DJ, Huo D. Evaluation of the quality of adjuvant endocrine therapy delivery for breast cancer care in the United States. JAMA Oncol. 2017;3(7):928–35. https://doi.org/10.1001/jamaoncol.2016.6380.CrossRefPubMedPubMedCentral

74.

Farias AJ, Du XL. Ethnic differences in initiation and timing of adjuvant endocrine therapy among older women with hormone receptor-positive breast cancer enrolled in Medicare Part D. Med Oncol. 2016;33(2):19. https://doi.org/10.1007/s12032-016-0732-1.CrossRefPubMedPubMedCentral

75.

Livaudais JC, Hershman DL, Habel L, Kushi L, Gomez SL, Li CI, et al. Racial/ethnic differences in initiation of adjuvant hormonal therapy among women with hormone receptor-positive breast cancer. Breast Cancer Res Treat. 2012;131(2):607–17. https://doi.org/10.1007/s10549-011-1762-1.CrossRefPubMed

76.

Biggers A, Shi Y, Charlson J, Smith EC, Smallwood AJ, Nattinger AB, et al. Medicare D subsidies and racial disparities in persistence and adherence with hormonal therapy. J Clin Oncol. 2016;34(36):4398–404. https://doi.org/10.1200/JCO.2016.67.3350.CrossRefPubMedPubMedCentral

77.

(EBCTCG) EBCTCG. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–717. https://doi.org/10.1016/S0140-6736(05)66544-0.CrossRef

78.

Jara Sánchez C, Ruiz A, Martín M, Antón A, Munárriz B, Plazaola A, et al. Influence of timing of initiation of adjuvant chemotherapy over survival in breast cancer: a negative outcome study by the Spanish Breast Cancer Research Group (GEICAM). Breast Cancer Res Treat. 2007;101(2):215–23. https://doi.org/10.1007/s10549-006-9282-0.CrossRefPubMed

79.

Buzdar AU, Smith TL, Powell KC, Blumenschein GR, Gehan EA. Effect of timing of initiation of adjuvant chemotherapy on disease-free survival in breast cancer. Breast Cancer Res Treat. 1982;2(2):163–9. https://doi.org/10.1007/bf01806452.CrossRefPubMed

80.

Hershman DL, Wang X, McBride R, Jacobson JS, Grann VR, Neugut AI. Delay of adjuvant chemotherapy initiation following breast cancer surgery among elderly women. Breast Cancer Res Treat. 2006;99(3):313–21. https://doi.org/10.1007/s10549-006-9206-z.CrossRefPubMed

81.

Colleoni M, Bonetti M, Coates AS, Castiglione-Gertsch M, Gelber RD, Price K, et al. Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group. J Clin Oncol. 2000;18(3):584–90. https://doi.org/10.1200/JCO.2000.18.3.584.CrossRefPubMed

82.

Nurgalieva ZZ, Franzini L, Morgan RO, Vernon SW, Liu CC, Du XL. Impact of timing of adjuvant chemotherapy initiation and completion after surgery on racial disparities in survival among women with breast cancer. Med Oncol. 2013;30(1):419. https://doi.org/10.1007/s12032-012-0419-1.CrossRefPubMed

83.

Fedewa SA, Ward EM, Stewart AK, Edge SB. Delays in adjuvant chemotherapy treatment among patients with breast cancer are more likely in African American and Hispanic populations: a national cohort study 2004-2006. J Clin Oncol. 2010;28(27):4135–41. https://doi.org/10.1200/JCO.2009.27.2427.CrossRefPubMed

84.

Katz SJ, Wallner LP, Abrahamse PH, Janz NK, Martinez KA, Shumway DA, et al. Treatment experiences of Latinas after diagnosis of breast cancer. Cancer. 2017;123(16):3022–30. https://doi.org/10.1002/cncr.30702.CrossRefPubMed

85.

Ramirez A, Perez-Stable E, Penedo F, Talavera G, Carrillo JE, Fernández M, et al. Reducing time-to-treatment in underserved Latinas with breast cancer: the Six Cities Study. Cancer. 2014;120(5):752–60. https://doi.org/10.1002/cncr.28450.CrossRefPubMed

86.

Power EJ, Chin ML, Haq MM. Breast cancer incidence and risk reduction in the Hispanic population. Cureus. 2018;10(2):e2235. https://doi.org/10.7759/cureus.2235.CrossRefPubMedPubMedCentral

87.

Akinyemiju T, Moore JX, Ojesina AI, Waterbor JW, Altekruse SF. Racial disparities in individual breast cancer outcomes by hormone-receptor subtype, area-level socio-economic status and healthcare resources. Breast Cancer Res Treat. 2016;157(3):575–86. https://doi.org/10.1007/s10549-016-3840-x.CrossRefPubMedPubMedCentral

88.

Siegel RL, Fedewa SA, Miller KD, Goding-Sauer A, Pinheiro PS, Martinez-Tyson D, et al. Cancer statistics for Hispanics/Latinos, 2015. CA Cancer J Clin. 2015;65(6):457–80. https://doi.org/10.3322/caac.21314.CrossRefPubMed

89.

Martínez ME, Gomez SL, Tao L, Cress R, Rodriguez D, Unkart J, et al. Contribution of clinical and socioeconomic factors to differences in breast cancer subtype and mortality between Hispanic and non-Hispanic white women. Breast Cancer Res Treat. 2017;166(1):185–93. https://doi.org/10.1007/s10549-017-4389-z.CrossRefPubMedPubMedCentral

90.

Ellis L, Canchola AJ, Spiegel D, Ladabaum U, Haile R, Gomez SL. Racial and ethnic disparities in cancer survival: the contribution of tumor, sociodemographic, institutional, and neighborhood characteristics. J Clin Oncol. 2018;36(1):25–33. https://doi.org/10.1200/JCO.2017.74.2049.CrossRefPubMed

91.

Warnecke RB, Campbell RT, Vijayasiri G, Barrett RE, Rauscher GH. Multilevel examination of health disparity: the role of policy implementation in neighborhood context, in patient resources, and in healthcare facilities on later stage of breast cancer diagnosis. Cancer Epidemiol Biomark Prev. 2019;28(1):59–66. https://doi.org/10.1158/1055-9965.EPI-17-0945.CrossRef

92.

Guan A, Lichtensztajn D, Oh D, Jain J, Tao L, Hiatt RA, et al. Breast cancer in San Francisco: disentangling disparities at the neighborhood level. Cancer Epidemiol Biomark Prev. 2019;28(12):1968–76. https://doi.org/10.1158/1055-9965.EPI-19-0799.CrossRef

93.

Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–52. https://doi.org/10.1038/35021093.CrossRefPubMed

94.

Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics. 2006;7:96. https://doi.org/10.1186/1471-2164-7-96.CrossRefPubMedPubMedCentral

95.

Network CGA. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70. https://doi.org/10.1038/nature11412.CrossRef

96.

Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 2008;14(5):1368–76. https://doi.org/10.1158/1078-0432.CCR-07-1658.CrossRefPubMed

97.

Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, et al. Basal-like subtype of invasive breast carcinoma immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10:5367–74.CrossRefPubMed

98.

Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98(19):10869–74. https://doi.org/10.1073/pnas.191367098.CrossRefPubMedPubMedCentral

99.

Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750–67. https://doi.org/10.1172/JCI45014.CrossRefPubMedPubMedCentral

100.

Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. J Am Med Assoc. 2006;295(21):2492–502.CrossRef

101.

Parise CA, Caggiano V. Disparities in race/ethnicity and socioeconomic status: risk of mortality of breast cancer patients in the California Cancer Registry, 2000-2010. BMC Cancer. 2013;13:449. https://doi.org/10.1186/1471-2407-13-449.CrossRefPubMedPubMedCentral

102.

Fejerman L, Serrano-Gómez S.J, Tamayo L. Breast cancer risk and mortality in women of Latin American Origin. In: Trapido AGREJ, editor. Advancing the Science of Cancer in Latinos Springer Open; 2020.

103.

Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27(8):1160–7. https://doi.org/10.1200/JCO.2008.18.1370.CrossRefPubMedPubMedCentral

104.

Sweeney C, Bernard PS, Factor RE, Kwan ML, Habel LA, Quesenberry CP Jr, et al. Intrinsic subtypes from PAM50 gene expression assay in a population-based breast cancer cohort: differences by age, race, and tumor characteristics. Cancer Epidemiol Biomark Prev. 2014;23(5):714–24. https://doi.org/10.1158/1055-9965.EPI-13-1023.CrossRef

105.

• Marker KM, Zavala VA, Vidaurre T, Lott PC, Vásquez JN, Casavilca-Zambrano S, et al. Human epidermal growth factor receptor 2–positive breast cancer is associated with Indigenous American ancestry in Latin American Women. Cancer Res. 2020. https://doi.org/10.1158/0008-5472.can-19-3659This study reported for the first time an association between Indigenous American ancestry and an increased risk for HER2-positive tumors in Latina women.

106.

Serrano-Gómez SJ, Sanabria-Salas MC, Garay J, Baddoo MC, Hernández-Suarez G, Mejía JC, et al. Ancestry as a potential modifier of gene expression in breast tumors from Colombian women. PLoS One. 2017;12(8):e0183179. https://doi.org/10.1371/journal.pone.0183179.CrossRefPubMedPubMedCentral

Title: Breast Cancer Health Disparities in Hispanics/Latinas
Authors: Silvia J. Serrano-Gomez
Maria Carolina Sanabria-Salas
Laura Fejerman
Publication date: 01-09-2020
Publisher: Springer US
Keywords: Breast Cancer
Breast Cancer
Published in: Current Breast Cancer Reports / Issue 3/2020
Print ISSN: 1943-4588
Electronic ISSN: 1943-4596
DOI: https://doi.org/10.1007/s12609-020-00370-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 3/2020

Surgical Approaches to the Prevention and Management of Breast Cancer–Related Lymphedema

The Role of Artificial Intelligence in Understanding and Addressing Disparities in Breast Cancer Outcomes

Impact of Genetic Ancestry on Treatment Toxicity and Racial Disparities in Breast Cancer

Do Women with Breast Cancer–related Lymphoedema Need to Wear Compression While Exercising?: Results from a Systematic Review and Meta-analysis

Disparities in Genetic Testing and Care Among Black Women with Hereditary Breast Cancer

Large Datasets for Disparities Research in Breast Cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer